{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:13:37Z","timestamp":1788783217845,"version":"build-2803163510"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    Propofol is commonly used to sedate patients, but variations in how individuals metabolize the drug may affect dosing requirements. The objective of this study was to explore how genetic variations in CYP450 enzymes, particularly\n                    <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic>\n                    , influence propofol metabolism in ICU patients receiving mechanical ventilation. Genetic variants of\n                    <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">CYP2C9<\/jats:italic>\n                    ,\n                    <jats:italic toggle=\"yes\">CYP2C19<\/jats:italic>\n                    , and\n                    <jats:italic toggle=\"yes\">CYP3A5<\/jats:italic>\n                    were collected from an institutional genetic data repository. Patients were dichotomized into low and high metabolic activity for each enzyme, and the mean weight- and time-normalized propofol dose administered was compared between groups via\n                    <jats:italic toggle=\"yes\">t<\/jats:italic>\n                    test. There was no significant difference in average daily propofol dose between patients with low and high\n                    <jats:italic toggle=\"yes\">CYP2B6<\/jats:italic>\n                    activity (11 vs. 11\u2005mg\/kg\/h,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u20050.78), or any of the other CYP enzymes analyzed (all\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&gt;\u20050.05). This study could not replicate previous studies indicating that patients carrying genetic variants with diminished CYP2B6 activity required lower propofol doses. Future studies with prospectively collected dosing and outcomes data, and measurement of plasma drug concentrations, may provide insights into personalized propofol dosing strategies.\n                  <\/jats:p>","DOI":"10.1097\/fpc.0000000000000570","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T06:00:08Z","timestamp":1748325608000},"page":"192-195","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacogenetic association of CYP enzymes with therapeutic propofol doses during mechanical ventilation"],"prefix":"10.1097","volume":"35","author":[{"given":"Chanel","family":"Hsiang","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Shakeel","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Farina","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Michigan Medicine, Ann Arbor, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, University of Utah, Salt Lake City, Utah, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Hertz","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of Michigan College of Pharmacy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"key":"R1-20250702","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJMra1208705","article-title":"Sedation and delirium in the intensive care unit.","volume":"370","author":"Reade","year":"2014","journal-title":"N Engl J Med"},{"key":"R2-20250702","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1007\/s00134-016-4344-1","article-title":"Clinical recommendations for pain, sedation, withdrawal and delirium assessment in critically ill infants and children: an ESPNIC position statement for healthcare professionals.","volume":"42","author":"Harris","year":"2016","journal-title":"Intensive Care Med"},{"key":"R3-20250702","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.medin.2019.09.010","article-title":"Oversedation zero as a tool for comfort, safety and intensive care unit management.","volume":"44","author":"Caballero","year":"2020","journal-title":"Med Intensiva (Engl Ed)"},{"key":"R4-20250702","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s40262-018-0672-3","article-title":"Clinical pharmacokinetics and pharmacodynamics of propofol.","volume":"57","author":"Sahinovic","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R5-20250702","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2133\/dmpk.DMPK-13-NT-092","article-title":"Association of the CYP2B6 c.516G>T polymorphism with high blood propofol concentrations in women from northern Greece.","volume":"29","author":"Mastrogianni","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"R6-20250702","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s13353-016-0373-2","article-title":"The effect of UGT1A9, CYP2B6 and CYP2C9 genes polymorphism on individual differences in propofol pharmacokinetics among Polish patients undergoing general anaesthesia.","volume":"58","author":"Mikstacki","year":"2017","journal-title":"J Appl Genet"},{"key":"R7-20250702","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s13318-015-0289-y","article-title":"Impact of the cytochrome P450 2B6 (CYP2B6) gene polymorphism c.516G>T (rs3745274) on propofol dose variability.","volume":"41","author":"Mour\u00e3o","year":"2016","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R8-20250702","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/bcpt.12277","article-title":"Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment.","volume":"115","author":"Khan","year":"2014","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R9-20250702","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1248\/bpb.b14-00671","article-title":"Impact of CYP2C9 polymorphism found in the Chinese population on the metabolism of propofol in vitro.","volume":"38","author":"Lian","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"R10-20250702","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ajhg.2018.04.001","article-title":"Association of polygenic risk scores for multiple cancers in a phenome-wide study: results from the Michigan Genomics Initiative.","volume":"102","author":"Fritsche","year":"2018","journal-title":"Am J Hum Genet"},{"key":"R11-20250702","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1007\/s00520-022-07118-y","article-title":"Lack of association of CYP2B6 pharmacogenetics with cyclophosphamide toxicity in patients with cancer.","volume":"30","author":"Hwang","year":"2022","journal-title":"Support Care Cancer"},{"key":"R12-20250702","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s00540-018-2470-3","article-title":"Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics.","volume":"32","author":"Kanaya","year":"2018","journal-title":"J Anesth"},{"key":"R13-20250702","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2005-03-1108","article-title":"The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen.","volume":"106","author":"Sconce","year":"2005","journal-title":"Blood"},{"key":"R14-20250702","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1056\/NEJMoa1310669","article-title":"A pharmacogenetic versus a clinical algorithm for warfarin dosing.","volume":"369","author":"Kimmel","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T13:33:44Z","timestamp":1785850424000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FPC.0000000000000570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000570","relation":{},"ISSN":["1744-6872","1744-6880"],"issn-type":[{"value":"1744-6872","type":"print"},{"value":"1744-6880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]}}}